Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Glucagon-like Peptide-1 Receptor Agonist Impact on Chronic Ocular Disease Including Age-Related Macular Degeneration

Ophthalmology(2025)10.1016/j.ophtha.2025.01.016Source: DataRank Database

Glucagon-like Peptide-1 Receptor Agonist Impact on Chronic Ocular Disease Including Age-Related Macular Degeneration is a research paper published in Ophthalmology (2025). On theSindex it has a DataRank of 0. It has been cited 44 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access44 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 27.98)OA: bronzeTopics (62)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Julia H. Joo ORCID,Sonia Kim ORCID,Jacqueline K. Shaia ORCID,David C. Kaelber ORCID,Rishi P. Singh ORCID

Live enrichment

PubMed:39863057 OpenAlex:https://openalex.org/W4406741757

Cleveland Eye Bank Foundation

Grant: P30EY025585

NCATS NIH HHS

Grant: UM1 TR004528

National Institutes of Health

Research to Prevent Blindness

Case Western Reserve University Clinical and Translational Science Collaborative

Cleveland Clinic Foundation

National Center for Advancing Translational Sciences

FWCI

27.98

Citation Percentile

1.0%

Citation Trend

2025

2026

bronzeLicense: http://creativecommons.org/licenses/by-nc-nd/4.0/

journalhttps://www.aaojournal.org/article/S0161-6420(25)00070-3/pdf

publisherhttps://www.aaojournal.org/article/S0161-6420(25)00070-3/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0161642025000703?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0161642025000703?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ophtha.2025.01.016

Fields of Study

Diabetes Treatment and ManagementRetinal Diseases and TreatmentsGlaucoma and retinal disordersHumansMaleFemaleRetrospective StudiesAgedGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsMiddle AgedGlaucoma, Open-AngleChronic DiseaseMetforminAspirinAged, 80 and overRisk FactorsOcular HypertensionWet Macular DegenerationMacular DegenerationCataractFollow-Up StudiesUnited StatesElectronic Health RecordsHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin

MeSH Terms

Glucagon-Like Peptide-1 Receptor AgonistsAgedAged, 80 and overAspirinCataractChronic DiseaseFemaleFollow-Up StudiesGlaucoma, Open-AngleHumansHypoglycemic AgentsInsulinMacular DegenerationMaleMetforminMiddle AgedOcular HypertensionRetrospective StudiesRisk FactorsUnited StatesHydroxymethylglutaryl-CoA Reductase InhibitorsWet Macular DegenerationElectronic Health Records

Keywords

MedicineMacular degenerationAgonistDegeneration (medical)DiseaseReceptorOphthalmologyInternal medicineAgingglaucomaAge-related macular degenerationDrug RepurposingGlp-1 Receptor Agonist

Sustainable Development Goals

SDG 0: Good health and well-being

Related Papers (1)

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

N/A

1.3DataRank · unranked

New England Journal of Medicine(2016)

co-cited

10.1056/nejmoa1603827